Refining clinical judgment of treatment outcome in obsessive-compulsive disorder

Psychiatry Research

Volumn 185, Issue 3, 2011, Pages 394-401

  Lewin, Adam B ^a   De Nadai, Alessandro S ^b   Park, Jennifer ^b   Goodman, Wayne K ^c   Murphy, Tanya K ^a   Storch, Eric A ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cognitive behavioral therapy; Drug therapy; Obsessive compulsive disorder; Treatment response; Yale Brown Obsessive Compulsive Scale

Indexed keywords

CYCLOSERINE; FLUOXETINE;

ACCURACY; ADULT; AGED; ARTICLE; CLINICAL DECISION MAKING; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PRACTICE; COGNITIVE THERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DISORDER; PREDICTIVE VALUE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; REMISSION; SENSITIVITY AND SPECIFICITY; SIGNAL DETECTION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; JUDGMENT; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; SIGNAL DETECTION, PSYCHOLOGICAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79251599288     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.08.021     Document Type: Article

References (51)

1. Abramowitz J.S., Taylor S., McKay D. Obsessive-compulsive disorder. Lancet 2009, 374(9688):491-499.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) 2000, American Psychiatric Association, Washington, D.C.
3. Arnold L.M., Rosen A., Pritchett Y.L., D'Souza D.N., Goldstein D.J., Iyengar S., Wernicke J.F. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005, 119:1-3.
4. Brown T.A., DiNardo P., Barlow D.H. Anxiety Disorders Interview Schedule Adult Version (ADIS-IV): Client Interview Schedule 2004, Oxford University Press, New York, NY.
5. Chen W.J., Faraone S.V., Biederman J., Tsuang M.T. Diagnostic accuracy of the Child Behavior Checklist scales for attention-deficit hyperactivity disorder: a receiver-operating characteristic analysis. Journal of Consulting and Clinical Psychology 1994, 62(5):1017-1025.
6. CMI-Group Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group. Archives of General Psychiatry 1991, 48(8):730-738.
7. Cohen J. Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychological Bulletin 1968, 70(4):213-220.
8. Cottraux J., Note I., Yao S.N., Lafont S., Note B., Mollard E., Bouvard M., Sauteraud A., Bourgeois M., Dartigues J.F. A randomized controlled trial of cognitive therapy versus intensive behavior therapy in obsessive compulsive disorder. Psychotherapy and Psychosomatics 2001, 70(6):288-297.
9. Deacon B.J., Abramowitz J.S. The Yale-Brown Obsessive Compulsive Scale: factor analysis, construct validity, and suggestions for refinement. Journal of Anxiety Disorders 2005, 19(5):573-585.
10. Eddy K.T., Dutra L., Bradley R., Westen D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clinical Psychology Review 2004, 24(8):1011-1030.
11. Farrar J.T. What is clinically meaningful: outcome measures in pain clinical trials. Clinical Journal of Pain 2000, 16(2 Suppl):S106-S112.
12. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV) 1996, American Psychiatric Press, Inc., Washington, DC.
13. Foa E.B., Liebowitz M.R., Kozak M.J., Davies S., Campeas R., Franklin M.E., Huppert J.D., Kjernisted K., Rowan V., Schmidt A.B., Simpson H.B., Tu X. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. American Journal of Psychiatry 2005, 162(1):151-161.
14. Frank E., Prien R.F., Jarrett R.B., Keller M.B., Kupfer D.J., Lavori P.W., Rush A.J., Weissman M.M. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Archives of General Psychiatry 1991, 48(9):851-855.
15. Gaffney G.R., Perry P.J., Lund B.C., Bever-Stille K.A., Arndt S., Kuperman S. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. Journal of the American Academy of Child and Adolescent Psychiatry 2002, 41(3):330-336.
16. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Delgado P., Heninger G.R., Charney D.S. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Archives of General Psychiatry 1989, 46(11):1012-1016.
17. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R.L., Hill C.L., Heninger G.R., Charney D.S. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Archives of General Psychiatry 1989, 46(11):1006-1011.
18. Guy W. Clinical Global Impressions ECDEU Assessment Manual for Psychopharmacology 1976, 218-222. National Institute for Mental Health, Rockville, MD, Vol. Revised DHEW Pub. (ADM).
19. Hollander E., Zohar J. Beyond refractory obsessions and anxiety states: toward remission. Journal of Clinical Psychiatry 2004, 65(14Suppl):3-5.
20. Jacobson N.S., Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. Journal of Consulting and Clinical Psychology 1991, 59(1):12-19.
21. Koran L.M. Quality of life in obsessive-compulsive disorder. Psychiatric Clinics of North America 2000, 23(3):509-517.
22. Kraemer H.C. The robustness of common measures of 2×2 association to bias due to misclassifications. The American Statistician 1985, 39(4):286-290.
23. Kraemer H.C. Evaluating Medical Tests: Objective and Quantitative Guidelines 1992, Sage Publications, Thousand Oaks, CA.
24. Kraemer H.C., Periyakoil V.S., Noda A. Kappa coefficients in medical research. Statistics in Medicine 2002, 21:2109-2129.
25. Leucht S., Davis J.M., Engel R.R., Kane J.M., Wagenpfeil S. Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology 2007, 32(9):1903-1910.
26. Lewin A.B., Piacentini J. Evidence-based assessment of child obsessive compulsive disorder: recommendations for clinical practice and treatment research. Child and Youth Care Forum 2010, 39:547-552.
27. McLean P.D., Whittal M.L., Thordarson D.S., Taylor S., Sochting I., Koch W.J., Paterson R., Anderson K.W. Cognitive versus behavior therapy in the group treatment of obsessive-compulsive disorder. Journal of Consulting and Clinical Psychology 2001, 69(2):205-214.
28. Meehl P.E. Clinical versus Statistical Prediction: A Theoretical Analysis and Review of the Evidence 1954, Rowan & Littlefield/Jason Aronson, Lanham, MD.
29. Owens E.B., Hinshaw S.P., Kraemer H.C., Arnold L.E., Abikoff H.B., Cantwell D.P., Conners C.K., Elliott G., Greenhill L.L., Hechtman L., Hoza B., Jensen P.S., March J.S., Newcorn J.H., Pelham W.E., Severe J.B., Swanson J.M., Vitiello B., Wells K.C., Wigal T. Which treatment for whom for ADHD? Moderators of treatment response in the MTA. Journal of Consulting and Clinical Psychology 2003, 71(3):540-552.
30. Pallanti S., Hollander E., Bienstock C., Koran L., Leckman J., Marazziti D., Pato M., Stein D., Zohar J. Treatment non-response in OCD: methodological issues and operational definitions. International Journal of Neuropsychopharmacology 2002, 5(2):181-191.
31. Pigott T.A., Pato M.T., Bernstein S.E., Grover G.N., Hill J.L., Tolliver T.J., Murphy D.L. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results. Archives of General Psychiatry 1990, 47(10):926-932.
32. Rider L.G., Giannini E.H., Harris-Love M., Joe G., Isenberg D., Pilkington C., Lachenbruch P.A., Miller F.W. Defining clinical improvement in adult and juvenile myositis. Journal of Rheumatology 2003, 30(3):603-617.
33. Shapira N.A., Ward H.E., Mandoki M., Murphy T.K., Yang M.C., Blier P., Goodman W.K. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biological Psychiatry 2004, 55(5):553-555.
34. Simpson H.B., Gorfinkle K.S., Liebowitz M.R. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: An open trial. Journal of Clinical Psychiatry 1999, 60(9):584-590.
35. Simpson H.B., Franklin M.E., Cheng J., Foa E.B., Liebowitz M.R. Standard criteria for relapse are needed in obsessive-compulsive disorder. Depression and Anxiety 2005, 21(1):1-8.
36. Simpson H.B., Huppert J.D., Petkova E., Foa E.B., Liebowitz M.R. Response versus remission in obsessive-compulsive disorder. Journal of Clinical Psychiatry 2006, 67(2):269-276.
37. Simpson H.B., Petkova E., Cheng J., Huppert J., Foa E., Liebowitz M.R. Statistical choices can affect inferences about treatment efficacy: a case study from obsessive-compulsive disorder research. Journal of Psychiatry Research 2008, 42(8):631-638.
38. Sousa M.B., Isolan L.R., Oliveira R.R., Manfro G.G., Cordioli A.V. A randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorder. Journal of Clinical Psychiatry 2006, 67(7):1133-1139.
39. Stein D.J., Andersen E.W., Tonnoir B., Fineberg N. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Current Medical Research and Opinion 2007, 23(4):701-711.
40. Storch E.A., Merlo L.J., Bengtson M., Murphy T.K., Lewis M.H., Yang M.C., Jacob M.L., Larson M., Hirsh A., Fernandez M., Geffken G.R., Goodman W.K. d-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. International Clinical Psychopharmacology 2007, 22(4):230-237.
41. Storch E.A., Merlo L.J., Lehmkuhl H., Geffken G.R., Jacob M., Ricketts E., Murphy T.K., Goodman W.K. Cognitive-behavioral therapy for obsessive-compulsive disorder: a non-randomized comparison of intensive and weekly approaches. Journal of Anxiety Disorders 2008, 22(7):1146-1158.
42. Swets J.A. Measuring the accuracy of diagnostic systems. Science 1988, 240(4857):1285-1293.
43. Swets J.A. Signal Detection Theory and ROC Analysis in Psychology and Diagnostics: Collected Papers 1996, Lawrence Erlbaum Associates, Hillsdale, NJ.
44. Swets J.A., Pickett R.M. Evaluation of Diagnostic Systems: Methods from Signal Detection Theory 1982, Academic Press, New York, NY.
45. Swets J.A., Dawes R.M., Monahan J. Psychological science can improve diagnostic decisions. Psychological Science in the Public Interest 2000, 1(1):1-26.
46. Task Force on Promotion and Dissemination of Psychological Procedures Training in and dissemination of empirically-validated psychological treatments: report and recommendations. The Clinical Psychologist 1995, 48:3-23.
47. Tolin D.F., Abramowitz J.S., Diefenbach G.J. Defining response in clinical trials for obsessive-compulsive disorder: a signal detection analysis of the Yale-Brown obsessive compulsive scale. Journal of Clinical Psychiatry 2005, 66(12):1549-1557.
48. van Oppen P., De Haan E., van Balkom A.J., Spinhoven P., Hoogduin K., Van Dyck R. Cognitive therapy and exposure in vivo in the treatment of obsessive compulsive disorder. Behaviour Research and Therapy 1995, 33:379-390.
49. Weisz J.R., Donenberg G.R., Han S.S., Weiss B. Bridging the gap between laboratory and clinic in child and adolescent psychotherapy. Journal of Consulting and Clinical Psychology 1995, 63(5):688-701.
50. Woody S.R., Steketee G., Chambless D.L. The usefulness of the Obsessive Compulsive Scale of the Symptom Checklist-90-Revised. Behaviour Research and Therapy 1995, 33(5):607-611.
51. Youden W.J. Index for rating diagnostic tests. Cancer 1950, 3(1):32-35.